Sight Sciences (SGHT) grants CFO 86,940 RSUs in equity award

Rhea-AI Filing Summary

Sight Sciences Chief Financial Officer James Rodberg received a grant of 86,940 restricted stock units (RSUs) of common stock on February 3, 2026 under the company’s 2021 Incentive Award Plan. The grant value is set at $562,500, divided by the stock’s closing price on the grant date.

The RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on Rodberg’s continued service. Each RSU converts into one share of common stock upon vesting. After this award, he beneficially owns 238,170 shares, including 198,719 unvested RSUs and 39,451 vested shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rodberg James

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	86,940	$0.00	--

Holdings After Transaction: Common Stock — 238,170 shares (Direct)

Footnotes (1)

1. Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing March 31, 2026 and continuing through December 31, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $562,500 divided by the closing price of the Common Stock on the grant date, which was February 3, 2026. Includes (i) 39,451 shares of Common Stock, and (ii) 198,719 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodberg James

(Last) (First) (Middle)

C/O SIGHT SCIENCES, INC.

4040 CAMPBELL AVE., SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		A		86,940(1)	A	$0	238,170(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing March 31, 2026 and continuing through December 31, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $562,500 divided by the closing price of the Common Stock on the grant date, which was February 3, 2026.

2. Includes (i) 39,451 shares of Common Stock, and (ii) 198,719 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested.

	/s/Jeremy Hayden, Attorney-in-Fact for James Rodberg	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Sight Sciences (SGHT) disclose about CFO James Rodberg’s new equity grant?

Sight Sciences disclosed that CFO James Rodberg received 86,940 restricted stock units on February 3, 2026, under its 2021 Incentive Award Plan. Each RSU represents one share of common stock that will be delivered as the units vest over time.

How is the value of James Rodberg’s RSU grant at Sight Sciences (SGHT) determined?

The RSU grant’s size is based on a fixed value of $562,500 divided by Sight Sciences’ common stock closing price on February 3, 2026. This formula determines the 86,940 RSUs awarded, tying the grant directly to the stock’s market price on the grant date.

What is the vesting schedule for the Sight Sciences (SGHT) CFO’s RSUs?

James Rodberg’s 86,940 RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029. Vesting is conditioned on his continued service with Sight Sciences at each quarterly vesting date, aligning compensation with long-term employment.

How many Sight Sciences (SGHT) shares does CFO James Rodberg beneficially own after this transaction?

After the RSU grant, James Rodberg beneficially owns 238,170 shares of Sight Sciences common stock. This total includes 39,451 currently held shares and 198,719 shares that will be received upon the vesting and settlement of unvested restricted stock units over time.

Does the Sight Sciences (SGHT) Form 4 indicate a purchase or sale by the CFO?

The Form 4 shows an acquisition of 86,940 shares in the form of restricted stock units granted at a price of $0 per share. It reflects stock-based compensation rather than an open-market purchase or sale by CFO James Rodberg of existing common shares.